PCSK1N and Alzheimer disease: Studies employing αSyn SAAs in AD patient cohorts have confirmed higher rates of αSyn co-pathology in patients with an AD-typical biomarker profile and have reported synergistic effects of αSyn and AD pathology on cognitive decline [33, 39–41], where αSyn SAA positive individuals show earlier cognitive decline after onset of amyloidosis [42].